Ring Mountain Capital LLC Purchases New Shares in Johnson & Johnson (NYSE:JNJ)

Ring Mountain Capital LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 2,196 shares of the company’s stock, valued at approximately $318,000.

A number of other hedge funds have also recently bought and sold shares of the company. Exencial Wealth Advisors LLC boosted its position in Johnson & Johnson by 2.3% in the 4th quarter. Exencial Wealth Advisors LLC now owns 44,573 shares of the company’s stock valued at $6,446,000 after buying an additional 1,000 shares during the last quarter. AMJ Financial Wealth Management boosted its position in Johnson & Johnson by 508.2% in the 4th quarter. AMJ Financial Wealth Management now owns 6,806 shares of the company’s stock valued at $160,000 after buying an additional 5,687 shares during the last quarter. Commerzbank Aktiengesellschaft FI boosted its position in Johnson & Johnson by 7.8% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 1,076,053 shares of the company’s stock valued at $155,619,000 after buying an additional 78,141 shares during the last quarter. Synergy Investment Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $380,000. Finally, Bahl & Gaynor Inc. boosted its position in shares of Johnson & Johnson by 303.0% in the 4th quarter. Bahl & Gaynor Inc. now owns 1,328,414 shares of the company’s stock worth $192,115,000 after purchasing an additional 998,761 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

JNJ opened at $165.22 on Thursday. The business’s 50-day moving average price is $152.11 and its two-hundred day moving average price is $156.19. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market capitalization of $397.79 billion, a price-to-earnings ratio of 24.85, a P/E/G ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.00%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on JNJ. Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Stifel Nicolaus reduced their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Guggenheim raised their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Finally, Morgan Stanley reduced their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.